193 related articles for article (PubMed ID: 9167419)
1. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
[TBL] [Abstract][Full Text] [Related]
2. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
[TBL] [Abstract][Full Text] [Related]
3. Profile of doxazosin in patients with benign prostatic hyperplasia.
Janknegt RA
Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
[TBL] [Abstract][Full Text] [Related]
4. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Kirby RS
Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
[TBL] [Abstract][Full Text] [Related]
5. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
[TBL] [Abstract][Full Text] [Related]
6. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
7. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
10. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
Kirby RS
Scand J Urol Nephrol Suppl; 1995; 168():29-33. PubMed ID: 7541549
[TBL] [Abstract][Full Text] [Related]
12. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
[TBL] [Abstract][Full Text] [Related]
13. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
16. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Siegel RL
Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
19. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Gerber GS; Contreras BA; Rukstalis DB
Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
[TBL] [Abstract][Full Text] [Related]
20. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]